SRC and cancer: In particular, the binding of TRI-BE to the SH2 domains in Src would block the recognition and interaction with the phosphorylated Y397 residue of FAK, suppressing the activation of the FAK/Src pathway [15] accompanied by a lower migratory and invasive capacity of cancer cells.